Short Communication

iMedPub Journals
http://www.imedpub.com

Journal of Biomarkers in Drug Development

2021
Vol. 2 No. 2 :107

In the Development of Psychiatric Drugs, New Approaches are being used

V.B Karsdal*

Division of Rheumatology, Duke Molecular Physiology Institute, Duke University School of Medicine, USA

Corresponding author:
Lanctot Marotta

vb.k.@duke.edu

Citation: Karsdal VB (2021) In the Development of Psychiatric Drugs, New Approaches are being used. J Biomark Drug Dev. Vol.2 No.2:107

Abstract

Insight into the functional processes that underpin central nervous system (CNS) dysfunction in psychiatric disorder is currently being bolstered by neuroscience. An increasing number of potential 'drugable' CNS targets have been found using sophisticated mechanism-based techniques, which may help both clinical care of psychiatric diseases and future psychiatric drug development. Psychiatry, on the other hand, has been unable to fully leverage the gains that neuroscience has yielded thus far. It's still unclear how many novel neuroscience-based targets are linked to the symptoms that make up psychiatric diagnostic entities, and stakeholders haven't agreed on how to proceed. Neuroscientists, clinicians, industry, and regulators must collaborate to overcome the translational gaps between novel targets, CNS functions, and clinical occurrences if psychiatry is to improve the condition of patients with psychiatric diseases by using mechanism-based CNS targets.

Keywords: Psychiatry; CNS; Neuroscience

Received: October 25, 2021; **Accepted:** November 06, 2021; **Published:** November 13, 2021

Introduction

The study of neuroscience is currently progressing in its understanding of the functional processes that underpin CNS dysfunction in psychiatric disorder. Such advancement has been made possible by the development of more advanced technologies in the field, such as neuroimaging and different 'omics'-technologies such as (epi) genomics, transcriptomics, proteomics, and metabolomics, to name a few [1]. Advances in other medical fields, such as clinical genetics and immunology, also help us understand brain problems better. In addition, novel approaches to quantifying human and animal behaviour, such as clinical phenotyping, open up new avenues for translational research. An increasing number of potential 'drug able' CNS targets have been found using advanced biological mechanism-based techniques, which may help both clinical therapy of psychiatric illnesses and future psychiatric drug development. However, one important source of concern is that psychiatry has so far been unable to fully leverage the improvements that neuroscience has provided [2]. It's still unclear how many innovative neuroscience-based targets link to symptoms or clinical expression of the illnesses that makes up mental diagnostic categories. As a result, stakeholders have yet to come to a consensus on how to proceed. A restricted number of innovative mechanisms of action are one component of the psychiatric drug approval backlog. Drugs with novel or drastically modified modes of action often arrive on the market in numerous fields, such as neurology and oncology. Since the introduction of monoamine reuptake inhibitors in the 1980's and 1990's, however, only a few mechanisms of action have been introduced in psychiatry [3]. The evolution of a 'innovation index,' which is defined as the number of mechanism of action divided by the number of registered medications, exemplifies this. Several variables contribute to the complexity of psychiatric medication development. First, due to the inviolability of the human brain, there are pharmacological limitations. It is difficult to penetrate the blood-brain barrier (BBB) and measure target engagement, and complicated procedures, such as in vivo positron emission tomography (PET) imaging, functional CNS testing, post-mortem studies, and CSF sampling, are necessary to determine this (in) directly [4].

The focus on structural anomalies in neurology helps in this regard. Second, there is a gap between the definition of the biological processes that underpin animal models and human research, limiting the discovery of cross-species clinically relevant pathways. As a result, findings from animal studies cannot be readily transferred into human therapeutic targets. Scientific breakthroughs, notably in genetics and immunology, have benefited innovative disease models in neurology. Third, psychiatric disorders have clinical heterogeneity because they are classified primarily on the basis of phenomenology in the Diagnostic and Statistical Manual of Mental Disorders (DSM), and

the neurobiological mechanisms underlying most disruptions of CNS functions (behavioural, emotional, and cognitive) are only partially understood [5]. A complex and interactive strategy to treating a psychiatric patient may be required. This is a difficult circumstance for medication development, and many large pharmaceutical companies have avoided it. Nonetheless, because psychiatric diseases have such a large social, economic, and personal burden, it is critical to develop innovative therapies that are only effective for a portion of the problem or for a subgroup of patients, or that merely supplement other pharmacological or psychosocial interventions. On the basis of continual pharmacological advances and clinical research with more modest results and expectations, most places can maintain a slow but steady supply of alternative or somewhat enhanced treatments.

Conclusion

Many facets of psychiatry are affected by new approaches to medication development in the field of psychiatry. This can only be done if all stakeholders work together early in the drug development process, while new scientific methods are still being verified. Not only should academia and industry collaborate closely with regulatory and advisory organisations, but so should patient societies and advocates. Communication between stakeholders is critical to achieving these lofty aims. Regular meetings, such as the ECNP meetings and conferences, can help with this. Furthermore, digital platforms can be used to improve communication with the goal of sharing expertise. The Innovative Medicines Initiative (IMI), for example, provides a pre-competitive forum for such collaborations.

References

1. Cohen AF, Burggraaf J, Van Gerven JMA, Moerland M, Groeneveld GJ (2015) The use of biomarkers in human pharmacology (Phase I) studies. Annu Rev Pharmacol Toxicol 55:55-74.
2. Collins FS, Varmus H (2015) A new initiative on precision medicine. N Engl J Med 372:793-795.
3. Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G (2005) Mechanism-based pharmacokinetic–pharmacodynamic modelling-A new classification of biomarkers. Pharm Res 22:1432-1437.
4. Harmer CJ, Duman RS, Cowen PJ (2017) How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry 27(2):141–142.
5. Peyrin-Biroulet L, Bressenot A, Kampman W (2014) Histologic remission: the ultimate therapeutic goal in ulcerative colitis? Clin Gastroenterol Hepatol 12:929-934.